RU2016133285A - Фармацевтические комбинации - Google Patents
Фармацевтические комбинации Download PDFInfo
- Publication number
- RU2016133285A RU2016133285A RU2016133285A RU2016133285A RU2016133285A RU 2016133285 A RU2016133285 A RU 2016133285A RU 2016133285 A RU2016133285 A RU 2016133285A RU 2016133285 A RU2016133285 A RU 2016133285A RU 2016133285 A RU2016133285 A RU 2016133285A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- pharmaceutical combination
- pharmaceutically acceptable
- pyridin
- amide
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 8
- 102400000932 Gonadoliberin-1 Human genes 0.000 claims 7
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims 7
- 239000000556 agonist Substances 0.000 claims 7
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 7
- 229960001442 gonadorelin Drugs 0.000 claims 7
- 239000000328 estrogen antagonist Substances 0.000 claims 6
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims 4
- IHGVAVLSTPCCJP-UHFFFAOYSA-N 4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C1C IHGVAVLSTPCCJP-UHFFFAOYSA-N 0.000 claims 4
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 4
- 108010069236 Goserelin Proteins 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229960001603 tamoxifen Drugs 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 2
- 229960002913 goserelin Drugs 0.000 claims 2
- 229960003690 goserelin acetate Drugs 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical group C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 108010037003 Buserelin Proteins 0.000 claims 1
- 206010061045 Colon neoplasm Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229960002184 abarelix Drugs 0.000 claims 1
- 108010023617 abarelix Proteins 0.000 claims 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical group C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000007295 breast benign neoplasm Diseases 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims 1
- 229960002719 buserelin Drugs 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 229960004622 raloxifene Drugs 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 229960002119 raloxifene hydrochloride Drugs 0.000 claims 1
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 208000009540 villous adenoma Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305057.3 | 2014-01-15 | ||
| EP14305057 | 2014-01-15 | ||
| PCT/IB2015/050260 WO2015107461A1 (en) | 2014-01-15 | 2015-01-13 | Pharmaceutical combinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020121929A Division RU2020121929A (ru) | 2014-01-15 | 2015-01-13 | Фармацевтические комбинации |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016133285A true RU2016133285A (ru) | 2018-02-20 |
| RU2016133285A3 RU2016133285A3 (enExample) | 2018-08-28 |
Family
ID=50033443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016133285A RU2016133285A (ru) | 2014-01-15 | 2015-01-13 | Фармацевтические комбинации |
| RU2020121929A RU2020121929A (ru) | 2014-01-15 | 2015-01-13 | Фармацевтические комбинации |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020121929A RU2020121929A (ru) | 2014-01-15 | 2015-01-13 | Фармацевтические комбинации |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160331755A1 (enExample) |
| EP (1) | EP3094340A1 (enExample) |
| JP (2) | JP2017502989A (enExample) |
| KR (1) | KR20160101027A (enExample) |
| CN (2) | CN112535688A (enExample) |
| AU (2) | AU2015207723A1 (enExample) |
| BR (1) | BR112016012141A2 (enExample) |
| CA (1) | CA2936783A1 (enExample) |
| MX (1) | MX2016009226A (enExample) |
| RU (2) | RU2016133285A (enExample) |
| WO (1) | WO2015107461A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019133674A1 (en) * | 2017-12-28 | 2019-07-04 | Constellation Pharmaceuticals, Inc. | Pharmacokinetic enhancement of ezh2 inhibitors through combination therapies |
| WO2023150267A1 (en) * | 2022-02-03 | 2023-08-10 | Maison Amori Oqvpo Llc | Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| US20080161355A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CN101019828A (zh) * | 2007-03-23 | 2007-08-22 | 济南帅华医药科技有限公司 | 一种含磷酸肌醇3－激酶抑制剂及激素类药物的抗癌组合物 |
| MX2009012066A (es) * | 2007-05-09 | 2009-11-19 | Novartis Ag | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| AR081823A1 (es) * | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
| PT2592933T (pt) * | 2010-07-16 | 2017-05-23 | Gaweco Anderson | Inibidores de mif e suas utilizações |
| CA2846454A1 (en) * | 2011-08-31 | 2013-05-10 | Novartis Ag | Synergistic combinations of pi3k- and mek-inhibitors |
| EP2827903A4 (en) * | 2012-03-23 | 2016-02-10 | Sloan Kettering Inst Cancer | POTENTIATION OF ANTIBODY-INDUCED COMPLEMENT-MEDIATED CYTOTOXICITY BY PI3K INHIBITION |
| US20150148345A1 (en) * | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
-
2015
- 2015-01-13 BR BR112016012141A patent/BR112016012141A2/pt not_active Application Discontinuation
- 2015-01-13 RU RU2016133285A patent/RU2016133285A/ru unknown
- 2015-01-13 AU AU2015207723A patent/AU2015207723A1/en not_active Abandoned
- 2015-01-13 RU RU2020121929A patent/RU2020121929A/ru unknown
- 2015-01-13 MX MX2016009226A patent/MX2016009226A/es unknown
- 2015-01-13 CA CA2936783A patent/CA2936783A1/en not_active Abandoned
- 2015-01-13 EP EP15701257.6A patent/EP3094340A1/en not_active Withdrawn
- 2015-01-13 WO PCT/IB2015/050260 patent/WO2015107461A1/en not_active Ceased
- 2015-01-13 JP JP2016546785A patent/JP2017502989A/ja not_active Withdrawn
- 2015-01-13 CN CN202011428621.1A patent/CN112535688A/zh active Pending
- 2015-01-13 US US15/109,704 patent/US20160331755A1/en not_active Abandoned
- 2015-01-13 CN CN201580004798.XA patent/CN105916515A/zh active Pending
- 2015-01-13 KR KR1020167018718A patent/KR20160101027A/ko not_active Abandoned
-
2017
- 2017-07-11 US US15/646,494 patent/US10085996B2/en not_active Expired - Fee Related
- 2017-10-10 AU AU2017245302A patent/AU2017245302B2/en not_active Ceased
-
2019
- 2019-09-13 JP JP2019167076A patent/JP2020023497A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017245302A1 (en) | 2017-11-02 |
| MX2016009226A (es) | 2016-10-05 |
| KR20160101027A (ko) | 2016-08-24 |
| EP3094340A1 (en) | 2016-11-23 |
| BR112016012141A2 (pt) | 2017-08-08 |
| CN105916515A (zh) | 2016-08-31 |
| US20160331755A1 (en) | 2016-11-17 |
| AU2017245302B2 (en) | 2019-04-04 |
| CA2936783A1 (en) | 2015-07-23 |
| US20170304311A1 (en) | 2017-10-26 |
| RU2020121929A (ru) | 2020-07-13 |
| RU2016133285A3 (enExample) | 2018-08-28 |
| WO2015107461A1 (en) | 2015-07-23 |
| JP2020023497A (ja) | 2020-02-13 |
| JP2017502989A (ja) | 2017-01-26 |
| AU2015207723A1 (en) | 2016-06-09 |
| CN112535688A (zh) | 2021-03-23 |
| US10085996B2 (en) | 2018-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2717911T3 (es) | Combinaciones farmacéuticas que comprenden un inhibidor de B-Raf, un inhibidor de EGFR y opcionalmente un inhibidor de PI3K-alfa | |
| CA2726734C (en) | Hdac inhibitor ms-275 and aromatase inhibitors for the treatment of cancer | |
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| JP2015511609A5 (enExample) | ||
| JP2019510832A5 (enExample) | ||
| SA521421440B1 (ar) | صياغات فموية من ناهضات مستقبل كابا الأفيوني | |
| Cho et al. | Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo | |
| HRP20160014T1 (hr) | Derivati 1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamida kao inhibitori fosfatidilinozitol 3-kinaze (pi3k), koji su korisni u lijeäśenju proliferativnih bolesti | |
| JP2006104221A5 (enExample) | ||
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| RU2017140674A (ru) | Способы лечения рака | |
| JP2018508516A5 (enExample) | ||
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| JP2016528246A5 (enExample) | ||
| JP2014523398A5 (enExample) | ||
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
| JP2015517523A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| IL273188B (en) | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor | |
| JP2019532047A5 (enExample) | ||
| JP2018519324A5 (enExample) | ||
| MX2015017058A (es) | Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos. | |
| RU2016133285A (ru) | Фармацевтические комбинации | |
| JP2015535283A5 (enExample) |